Pediatric lymphomas: recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood.
The importance of staging and classification of pediatric lymphomas is underscored by modern results of clinical trials from many centers and multi-institutional cooperative groups worldwide. Increasing sophistication in immunopathologic classification of the high-grade, aggressive non-Hodgkin's lymphomas (NHLs) characteristic of childhood and adolescence has clarified recognition of a new clinicopathologic entity with predilection for the young, i.e., Ki-1-positive (CD30-positive) anaplastic large-cell lymphoma (ALCL) which accounts for approximately 8-12% of all pediatric NHLs. Even though the majority of ALCLs present with nonlocalized advanced stage (III or IV) disease at diagnosis, five-year survival is in the range of 75-85% from seven reported series of pediatric patients treated with modern multidrug therapy. Further study of this comparatively uncommon entity is needed.